Literature DB >> 17933718

The epidemiology of HIV coreceptor tropism.

Christian Hoffmann1.   

Abstract

According to their cellular coreceptor tropism, HIV variants are termed R5 if they use CCR5 as a coreceptor, whereas viruses with a preference for CXCR4 are termed X4. The prevalence of R5, X4 and dual/mixed (D/M) strains shows considerable variation in different patient populations. In treatment naive patients, R5 strains are found in 80-90%, compared to only 50-55% in patients with antiretroviral exposure. The most important predictor of R5 tropism seems to be a higher CD4 T-cell count in both naive and antiretrovirally pretreated patients. A low HIV plasma viremia seems to be associated with R5 tropism only in untreated patients. As the benefit of the new antiretroviral drug class of the CCR5 coreceptor antagonists will be probably limited to the HIV-infected patients harbouring R5 strains, determination of viral coreceptor tropism has become an important diagnostic prerequisite for the treatment of HIV infection. This review will focus on current knowledge of the epidemiology of HIV coreceptor tropism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17933718

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  15 in total

Review 1.  The clinical applications of genome editing in HIV.

Authors:  Cathy X Wang; Paula M Cannon
Journal:  Blood       Date:  2016-04-06       Impact factor: 22.113

2.  Clinical Applications of Genome Editing to HIV Cure.

Authors:  Cathy X Wang; Paula M Cannon
Journal:  AIDS Patient Care STDS       Date:  2016-11-17       Impact factor: 5.078

3.  Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.

Authors:  Olga Latinovic; Janaki Kuruppu; Charles Davis; Nhut Le; Alonso Heredia
Journal:  Clin Med Ther       Date:  2009

4.  Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection.

Authors:  Chuka A Didigu; Craig B Wilen; Jianbin Wang; Jennifer Duong; Anthony J Secreto; Gwenn A Danet-Desnoyers; James L Riley; Phillip D Gregory; Carl H June; Michael C Holmes; Robert W Doms
Journal:  Blood       Date:  2013-10-25       Impact factor: 22.113

Review 5.  Clinical use of CCR5 inhibitors in HIV and beyond.

Authors:  Bruce L Gilliam; David J Riedel; Robert R Redfield
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

6.  The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa.

Authors:  Quazi Ataher; Simon Portsmouth; Laura A Napolitano; Sybil Eng; Anna Greenacre; Andrew Kambugu; Robin Wood; Sharlaa Badal-Faesen; Randy Tressler
Journal:  J Int AIDS Soc       Date:  2012-01-26       Impact factor: 5.396

Review 7.  Novel approaches to inhibit HIV entry.

Authors:  Chukwuka A Didigu; Robert W Doms
Journal:  Viruses       Date:  2012-02-21       Impact factor: 5.048

Review 8.  Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches.

Authors:  Mariana Santa-Marta; Paula Matos de Brito; Ana Godinho-Santos; Joao Goncalves
Journal:  Front Immunol       Date:  2013-10-24       Impact factor: 7.561

9.  Understanding the HIV coreceptor switch from a dynamical perspective.

Authors:  Christel Kamp
Journal:  BMC Evol Biol       Date:  2009-11-30       Impact factor: 3.260

Review 10.  Gene therapy targeting HIV entry.

Authors:  Chuka Didigu; Robert Doms
Journal:  Viruses       Date:  2014-03-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.